Pitfalls in the response evaluation after peptide receptor radionuclide therapy with [ 177 Lu-DOTA 0 ,Tyr 3 ]octreotate
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pitfalls in the response evaluation after peptide receptor radionuclide therapy with [
177
Lu-DOTA
0
,Tyr
3
]octreotate
Authors
Keywords
-
Journal
ENDOCRINE-RELATED CANCER
Volume 24, Issue 5, Pages 243-251
Publisher
Bioscientifica
Online
2017-03-21
DOI
10.1530/erc-16-0524
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
- (2017) Jonathan Strosberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Transient early increase in thyroglobulin levels post-radioiodine ablation in patients with differentiated thyroid cancer
- (2015) Ivan Stevic et al. CLINICAL BIOCHEMISTRY
- Peptide Receptor Radionuclide Therapy–Induced Hepatotoxicity in Patients With Metastatic Neuroendocrine Tumors
- (2015) Brian P. Riff et al. CLINICAL NUCLEAR MEDICINE
- Specific efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced neuroendocrine tumours of the small intestine
- (2015) Amir Sabet et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Subacute haematotoxicity after PRRT with 177Lu-DOTA-octreotate: prognostic factors, incidence and course
- (2015) Hendrik Bergsma et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Renal function affects absorbed dose to the kidneys and haematological toxicity during 177Lu-DOTATATE treatment
- (2015) Johanna Svensson et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors
- (2014) Lisa Bodei et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature
- (2013) M Fraenkel et al. ENDOCRINE-RELATED CANCER
- Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: Experience of two decades of cancer registry
- (2013) Catharina M. Korse et al. EUROPEAN JOURNAL OF CANCER
- Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate
- (2013) Amir Sabet et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Long-Term Hematotoxicity After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate
- (2013) A. Sabet et al. JOURNAL OF NUCLEAR MEDICINE
- Comparison of Response Evaluation in Patients with Gastroenteropancreatic and Thoracic Neuroendocrine Tumors After Treatment with [177Lu-DOTA0,Tyr3]Octreotate
- (2013) E. I. van Vliet et al. JOURNAL OF NUCLEAR MEDICINE
- Renal and Hematological Toxicity in Patients of Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE
- (2012) Santosh K. Gupta et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- 90Y Radioembolization After Radiation Exposure from Peptide Receptor Radionuclide Therapy
- (2012) S. Ezziddin et al. JOURNAL OF NUCLEAR MEDICINE
- Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study
- (2011) Lisa Bodei et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [90Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers
- (2011) Anna Imhof et al. JOURNAL OF CLINICAL ONCOLOGY
- Radioembolization (Yttrium-90 Microspheres) for Primary and Metastatic Hepatic Malignancies
- (2010) Andrew S. Kennedy et al. CANCER JOURNAL
- 90Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide
- (2010) David L. Bushnell et al. JOURNAL OF CLINICAL ONCOLOGY
- Lymphocytic Toxicity in Patients After Peptide-Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC
- (2009) Maribel L. Sierra et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors
- (2008) Lisa Bodei et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival
- (2008) Dik J. Kwekkeboom et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search